Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia - PubMed (original) (raw)
. 1998 Jul 1;9(10):1481-6.
doi: 10.1089/hum.1998.9.10-1481.
K Mäkinen, H Manninen, P Matsi, M Kossila, R S Agrawal, T Pakkanen, J S Luoma, H Viita, J Hartikainen, E Alhava, M Laakso, S Ylä-Herttuala
Affiliations
- PMID: 9681419
- DOI: 10.1089/hum.1998.9.10-1481
Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia
M Laitinen et al. Hum Gene Ther. 1998.
Abstract
Arterial gene transfer offers a promising new approach for the treatment of vascular disorders. However, no data are available about the gene transfer efficiency in human arteries in vivo. The aim of this study was to evaluate the safety and feasibility of catheter-mediated adenoviral gene transfer in human peripheral arteries. Ten patients (8 females, 2 males, mean age 80 +/- 8 years) suffering from chronic critical leg ischemia with a prior decision for amputation were recruited in the study. Gene transfer was performed in eight patients in conjunction with a conventional percutaneous transluminal angioplasty, using a perfusion coil balloon catheter. Two patients served as controls. Increasing concentrations of replication-deficient adenoviruses (titers from 1 x 10(8) to 4 x 10(10) PFU) containing a nuclear-targeted beta-galactosidase marker gene were administered into the arteries over 10 min via the catheter. Amputations were performed 20 to 51 hr after the procedures and gene transfer efficiency was evaluated in the transduced arteries using X-Gal staining for beta-galactosidase activity. Beta-galactosidase gene transfer was well tolerated and no adverse tissue responses or systemic complications were observed in any of the patients. Gene transfer was successful in six of the eight patients. Gene transfer efficiency varied between 0.04 and 5.0% of all arterial cells. Transgene expression was detected in smooth muscle cells, endothelial cells, and macrophages and in tunica adventitia. However, transgene activity was not evenly distributed in the arterial wall and no transgene activity was found beneath advanced atherosclerotic lesions. The safety and feasibility of in vivo gene transfer by adenoviral vectors to human peripheral arteries were established. Although improvements are still required in gene transfer efficiency, these findings suggest that adenoviruses can be used to deliver therapeutically active genes into human arteries.
Similar articles
- Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses.
Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen J, Lehtolainen P, Viita H, Paljärvi L, Vanninen R, Ylä-Herttuala S. Puumalainen AM, et al. Hum Gene Ther. 1998 Aug 10;9(12):1769-74. doi: 10.1089/hum.1998.9.12-1769. Hum Gene Ther. 1998. PMID: 9721087 Clinical Trial. - Adenoviral vector-mediated gene transfer into sheep arteries using a double-balloon catheter.
Rome JJ, Shayani V, Newman KD, Farrell S, Lee SW, Virmani R, Dichek DA. Rome JJ, et al. Hum Gene Ther. 1994 Oct;5(10):1249-58. doi: 10.1089/hum.1994.5.10-1249. Hum Gene Ther. 1994. PMID: 7849097 - Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector.
Steg PG, Feldman LJ, Scoazec JY, Tahlil O, Barry JJ, Boulechfar S, Ragot T, Isner JM, Perricaudet M. Steg PG, et al. Circulation. 1994 Oct;90(4):1648-56. doi: 10.1161/01.cir.90.4.1648. Circulation. 1994. PMID: 7923648 - Coronary restenosis and gene therapy.
Mazur W, Ali NM, Raizner AE, French BA. Mazur W, et al. Tex Heart Inst J. 1994;21(1):104-11. Tex Heart Inst J. 1994. PMID: 8180504 Free PMC article. Review. - Adenovirus-mediated gene transfer to cerebral circulation.
Ooboshi H, Ibayashi S, Heistad DD, Fujishima M. Ooboshi H, et al. Mech Ageing Dev. 2000 Jul 31;116(2-3):95-101. doi: 10.1016/s0047-6374(00)00123-8. Mech Ageing Dev. 2000. PMID: 10996009 Review.
Cited by
- Phosphorylation regulates FOXC2-mediated transcription in lymphatic endothelial cells.
Ivanov KI, Agalarov Y, Valmu L, Samuilova O, Liebl J, Houhou N, Maby-El Hajjami H, Norrmén C, Jaquet M, Miura N, Zangger N, Ylä-Herttuala S, Delorenzi M, Petrova TV. Ivanov KI, et al. Mol Cell Biol. 2013 Oct;33(19):3749-61. doi: 10.1128/MCB.01387-12. Epub 2013 Jul 22. Mol Cell Biol. 2013. PMID: 23878394 Free PMC article. - Virus-mediated gene transfer to induce therapeutic angiogenesis: where do we stand?
Giacca M. Giacca M. Int J Nanomedicine. 2007;2(4):527-40. Int J Nanomedicine. 2007. PMID: 18203421 Free PMC article. Review. - Cardiovascular Gene Therapy: Past, Present, and Future.
Ylä-Herttuala S, Baker AH. Ylä-Herttuala S, et al. Mol Ther. 2017 May 3;25(5):1095-1106. doi: 10.1016/j.ymthe.2017.03.027. Epub 2017 Apr 4. Mol Ther. 2017. PMID: 28389321 Free PMC article. Review. - Gene therapy for restenosis: current status.
Rutanen J, Markkanen J, Ylä-Herttuala S. Rutanen J, et al. Drugs. 2002;62(11):1575-85. doi: 10.2165/00003495-200262110-00001. Drugs. 2002. PMID: 12109921 Review. - Human studies of angiogenic gene therapy.
Gupta R, Tongers J, Losordo DW. Gupta R, et al. Circ Res. 2009 Oct 9;105(8):724-36. doi: 10.1161/CIRCRESAHA.109.200386. Circ Res. 2009. PMID: 19815827 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources